Bevacizumab in Combination with folfiri Chemotherapy in Patients with Metastatic Colorectal Cancer: An Assessment of Safety and Efficacy in the Province of Newfoundland and Labrador

Background: In 2005, bevacizumab was approved by Health Canada for patients with metastatic colorectal cancer (mcrc). Newfoundland and Labrador was one of the first Canadian provinces to fund this agent in combination with FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) chemotherapy. In this analys...

Full description

Bibliographic Details
Published in:Current Oncology
Main Authors: G. Dranitsaris, S. Edwards, J. Edwards, M. Leblanc, R. Abbott
Format: Text
Language:English
Published: Multidisciplinary Digital Publishing Institute 2010
Subjects:
bevacizumab
colorectal cancer
metastatic
safety
folfiri
Canada
Meier
Newfoundland
Online Access:https://doi.org/10.3747/co.v17i5.592

Similar Items